Study Summary
This trial finds that MRI-guided prostate SBRT is safe for patients with metastatic prostate cancer, with similar quality of life outcomes to those without metastatic prostate cancer.
Eligible Conditions
- Hormone-Refractory Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: baseline, 3-6months and at 9-12 months.
Month 12
Change in Number of Subjects with Adverse events will be collected
Change in Quality of life questionnaires will be assessed.
Change in The International Prostate Symptom Score (I-PSS) will be assessed.
Trial Safety
Safety Progress
Trial Design
0 Treatment Group
20 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 3-6months and at 9-12 months.
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
986 Previous Clinical Trials
1,338,485 Total Patients Enrolled
Josephine Kang, M.D.,Ph.D.Principal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
50 Total Patients Enrolled
Ariel Marciscano, M.D.Principal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
50 Total Patients Enrolled
Eligibility Criteria
Age 18 - 90 · Male Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have a biopsy-proven diagnosis of prostate adenocarcinoma.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments